MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and related diseases announced the recent decision of the German Patent Register to grant MEDITE the German priority patent for its Histology "Lab-in-one Automation" System. Based on this success MEDITE will finish its nationalization applications for USA, China and UK before April 4th, 2015.
Similar to the highly automated clinical laboratory industry, the anatomic pathology laboratory industry is about to undergo an automation transformation. MEDITE's new patent serves again as the forerunner in transitioning the industry towards automation. This "Lab-in–One Automation" technology will revolutionize the automation of pathology laboratories by combining many disparate systems into one complete automated histology laboratory. Biopsies are automatically processed into microscopy slides ready for diagnosis and digitalization.
The "Lab-in-one Automation" fully automates 24 by 7 tissue processing, embedding, sectioning, staining, cover-slipping and digital slide scanning according to Michaela Ott, CEO of MEDITE.
The patented "Lab-In-One" device, which utilizes state of the art robotic and laser technology, is designed to fulfill the need for increased volume throughput emanating from increased demand from large laboratories in the US and other countries, including highly populated countries like China. This innovative technology reduces the cycle time from 24 to 48 hours down to 1 hour for up to 400,000 slides per year. The technology is based on MEDITE's partially automated systems now combined into a new closed and computer controlled system including an automated sectioning device.
In successfully integrating these systems, we overcame significant technological hurdles. This technology also significantly integrates histology results into the digital Laboratory Information Systems as a method for fully documenting and supporting the diagnoses. MEDITE believes the "Lab-in–One Automation" technology can serve as an integral factor for the standardization desired by most of the industry's laboratories and customers. Most of the consumables currently used, and in particular the use of hazardous reagents for decalcifying and processing the biopsies like acids, xylene and formalin, are no longer needed which significantly improves the laboratory working environment. The operating costs of running an average histology lab can be reduced by over 50% from existing levels.
MEDITE is strategically positioned to meet the demand for more efficient and less costly medical care solutions in cancer diagnostics, along with addressing the current shortage of trained histotechs. We expect to start marketing the "Lab-in–One Automation" systems reflecting this leap in technology in the next 2-3 years contingent upon the availability of developmental resources. The 20 years patent protection securing MEDITE's proprietary technology should allow the company to obtain a major portion of this billion dollar market.
SOURCE MEDITE Cancer Diagnostics, Inc.